Overview

Tucatinib is a reversible, HER2-selective small-molecule tyrosine kinase inhibitor that binds the intracellular ATP site of HER2 without broadly blocking EGFR, which spares much of the skin and gut toxicity seen with pan-HER agents. Its compact kinase selectivity is precisely why it reaches therapeutic levels in the brain. Supplied as 150 mg tablets in an 84-tablet pack, it is almost always used with trastuzumab and capecitabine, so the mechanism only makes sense inside that three-drug context. Selectivity, not raw potency, defines its clinical niche.

How It Works

Tucatinib occupies the adenosine-triphosphate binding pocket of the HER2 intracellular kinase domain, preventing autophosphorylation and the downstream activation of the PI3K–AKT and MAPK pathways that drive proliferation and survival. Because it favors HER2 over EGFR, normal epidermal signaling is largely preserved, reducing rash and diarrhea. Critically, its small size and selectivity permit meaningful penetration of the blood–brain barrier, so intracranial HER2 clones are exposed to active drug. This intracellular interruption is what differentiates it from larger antibody-based HER2 therapies.

Indications

Tucatinib is indicated for HER2-positive metastatic breast cancer, including patients with active brain metastases, and for certain HER2-positive colorectal cancers, in combination with trastuzumab and capecitabine. Prior trastuzumab exposure is typical. Selection relies on confirmed HER2 positivity, often by IHC and ISH. The regimen continues while benefit is observed, with the CNS component monitored by imaging given the drug's brain activity.

Dosage & Administration

The oral dose is 300 mg twice daily, assembled from two 150 mg tablets about 12 hours apart, taken with the companion trastuzumab infusion and capecitabine. Tablets are swallowed whole with or without food. The 84-tablet pack covers a defined course window. Dose holds follow protocol for hepatic signals or diarrhea, and the three agents are timed together to maintain coordinated HER2 and cytotoxic pressure.

Storage & Sourcing

Store 150 mg tablets at 2–8 °C in the original container, protected from moisture and light; do not freeze. Ship under a documented refrigerated chain and verify batch, expiry, and tamper seals on receipt. Rotate stock by earliest expiry. Keep the tucatinib, trastuzumab, and capecitabine components in reconcilable batches to support the combination course.

FAQ

Q: Why is tucatinib described as HER2-selective rather than pan-HER?

A: It binds HER2 with far greater preference than EGFR, so normal skin and gut EGFR signaling is largely spared, which limits the rash and diarrhea typical of broader HER inhibitors.

Q: How does tucatinib achieve activity against brain metastases?

A: Its small, selective molecule penetrates the blood–brain barrier far better than large anti-HER2 antibodies, exposing intracranial tumor clones to active kinase inhibition.

Q: What intracellular pathway does tucatinib interrupt?

A: It blocks HER2 autophosphorylation, cutting downstream PI3K–AKT and MAPK signaling that would otherwise drive tumor-cell survival and division.

Q: Why is tucatinib given with trastuzumab and capecitabine?

A: Trastuzumab adds extracellular HER2 blockade and capecitabine contributes cytotoxic effect, so the trio covers the receptor from outside, inside, and via chemotherapy at once.